---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-069559"
form_type: "8-K"
ticker: "IOBTQ"
cik: "0001865494"
company_name: "IO Biotech, Inc."
filed_at: "2023-03-14T23:59:59+00:00"
generated_at: "2026-06-18T03:57:02.363019+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# IO Biotech reports ~$142M cash as of Dec 31, 2022; runway through Q3 2024

## Summary
- Preliminary cash and cash equivalents of ~$142M as of Dec 31, 2022 (subject to audit).
- Cash runway projected through Q3 2024, per updated corporate presentation.
- Updated presentation to be used at Oppenheimer 33rd Annual Healthcare Conference on Mar 14, 2023.
- No other financial results or guidance changes disclosed; preliminary cash is unaudited.

## SEC filing metadata
- accession: 0001193125-23-069559
- form_type: 8-K
- ticker: IOBTQ
- cik: 0001865494
- company_name: IO Biotech, Inc.
- filed_at: 2023-03-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1865494/000119312523069559/0001193125-23-069559-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1865494/000119312523069559/d486492d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-069559
- JSON: https://secwatch.observer/filing/0001193125-23-069559.json
- Plain text: https://secwatch.observer/filing/0001193125-23-069559.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.